Canopy Growth Corp.: Could it Hit $20 by Year-End?

Canopy Growth Corp. (TSX:WEED) continues to reinforce its leadership position in the medical marijuana market. Is 100% upside on the way?

| More on:

Canopy Growth Corp. (TSX:WEED) is back down to $10 per share and investors are wondering if a double might be in the cards before next year.

Let’s take a look at the current situation to see if this is the right time to add the stock to your portfolio.

Recreational market hopes

Canopy and its peers are trading at sky-high valuations based on investor expectations that Canada will open its recreational marijuana market in July 2018.

It’s easy to see why the hype is holding up.

The federal government has met its targets to date, much to the surprise of many pundits. The task force submitted its report as expected at the end of November, and the Liberals introduced the first look at the legislation April 13, which was right on schedule.

Once passed, the plan will provide a legal framework for the opening of the recreational market by Canada Day next year.

Are investors too optimistic?

The provinces and territories will be responsible for administering the programs in their own back yards. This includes setting prices and overseeing the operations of the industry.

The market appears to believe the provinces will have all their ducks lined up by next summer, but there are serious decisions that have to be made in a short period of time.

Pricing is just one component that will have to be ironed out. If marijuana is taxed too heavily, there is a risk buyers will simply turn to the black market. On the other hand, if the tax revenue is too low, cash-strapped provinces might find themselves facing a new money pit.

Deciding who gets to sell marijuana, and where, is also going to take some careful planning. Given the potential size of the market, there is a lot of money at stake, and politicians are going to want to get it right.

As such, it wouldn’t be a surprise to see the provinces drag their feet on this matter.

Is Canopy attractive?

Canopy is doing all the right things at this point in the market’s evolution.

The company is the dominant player in the growing medical marijuana space, with strong market share in Canada and strategic positions overseas.

Canopy’s leadership was made more evident recently with the announcement that three of Canada’s smaller players have signed up to supply product to Canopy’s Craft Grow program on a wholesale basis.

Through the Tweed Main Street online marketplace, smaller companies and new entrants can expand their reach while avoiding the costs and risks involved in trying to set up their own sales and service platforms.

The market is still evolving, but Canopy is definitely on the right track.

Is 100% upside possible by 2018?

Canopy and its peers appear to be priced for perfection, so any significant move to the upside in the coming months would likely require strong indications from the provinces that they will indeed be ready to launch next summer.

At this point, I have my doubts that will happen, so new buyers of the stock might want to be careful betting on a big gain in the near term. In fact, there is a risk things could go the other way, especially if the provinces start to kick the can down the road.

Canopy is definitely a top name in the sector, but at the current valuation, it might be a good idea to keep any position small.

Looking for more research?

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Andrew Walker has no position in any stocks mentioned.

More on Investing

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Woman has an idea
Investing

3 No-Brainer Stocks to Buy With $200 Right Now

These three stocks are no-brainer buys, given their solid underlying businesses and healthy growth prospects.

Read more »

Investing

2 Stocks I’m Loading Up on in 2024

Alimentation Couche-Tard (TSX:ATD) and another stock that are getting too cheap after their latest corrections.

Read more »

grow money, wealth build
Dividend Stocks

1 Top Dividend Stock That Can Handle Any Kind of Market (Even Corrections)

While most dividend aristocrats can maintain their payouts during weak markets, very few can maintain a healthy valuation or bounce…

Read more »

Red siren flashing
Dividend Stocks

Income Alert: These Stocks Just Raised Their Dividends

Three established dividend-payers from different sectors are compelling investment opportunities for income-focused investors.

Read more »

online shopping
Tech Stocks

1 Hidden Catalyst That Could Ignite Shopify Stock

Here's why Shopify (TSX:SHOP) ought to remain a top growth stock investors continue to focus on for the long haul.

Read more »

Oil pumps against sunset
Energy Stocks

Is it Too Late to Buy Enbridge Stock?

Besides its juicy and sustainable dividends, Enbridge’s improving long-term growth prospects make it a reliable stock to hold for the…

Read more »

Man considering whether to sell or buy
Tech Stocks

WELL Stock: Buy, Sell, or Hold?

WELL stock has a lot of upside as the company is likely to continue to grow, posting positive earnings in…

Read more »